AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 41 min read$OSCR

McAnaney Adam sold $216K of OSCR

McAnaney Adam (Chief Legal Officer) sold 9,859 shares of Oscar Health, Inc. (OSCR) at an average of $21.94 ($21.74–$22.45, $0.22M total) across 2 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McAnaney Adam
Published Jun 4, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The disclosed sale adds transparency but is unlikely to move the stock significantly.

02

Market read

Provides fresh insider transaction data; modest relevance for short‑term traders.

03

What to watch

Potential tax‑loss harvesting or diversification unrelated to company outlook.

Relevance 3/10Novelty 3/10Timing: filing date 2026-06-04, after‑hours

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is pre‑arranged and often neutral.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

Chief Legal Officer sold 9,859 shares for $216K via 10b5-1 plan, disclosed in Form 4 filing.

Expected impact

slight downward pressure as market absorbs insider sell.

Evidence & confidence

The sale size is modest but disclosed via a 10b5‑1 plan, which can prompt short‑term selling.

Market effects

Sector

Minimal impact on health‑tech sector; insider activity is routine.

Regional

No broader regional effect.

Global

Limited to Oscar Health investors.

Counterpoint

What could challenge this read

The sale could be purely portfolio‑rebalancing, not a negative signal.

Key entities

  • company
    Oscar Health, Inc.

    US‑listed health‑tech insurer (ticker OSCR).

  • person
    McAnaney Adam

    Chief Legal Officer of Oscar Health, insider reporter.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OSCR insider trading history →

Related articles

SEP 16
$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

gurufocus.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

tipranks.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.

scanx.trade2 min